A practical guide to interim injunctions
Fierce battles between branded and generic pharmaceutical companies have been played out in the English courts. Brian Whitehead, Stuart Jackson and Richard Kempner provide effective strategies for both obtaining and avoiding interim injunctions
Many generic pharmaceutical manufacturers have adopted a strategy of manufacturing and selling pharmaceutical products that are protected by a third party's patent. In addition to targeting and selling products protected only by formulation patents, which may be more vulnerable to...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.